Quality Is Making A Come-Back

Rudi Filapek-Vandyck

Look closely, and investors will see that quality stocks are making a comeback after being left by the wayside in the Trump-inspired reflation trade last year. CSL is trading around $128. Ramsay Health Care is back around $70. Amcor is well above $15, and InvoCare is approaching its all-time high... Show More

Investment foresight lifts CSL profit

Andrew Stanley

Blood plasma producer, CSL (ASX:CSL), upgraded its profit forecasts in January and it is now targeting 18-20% profit growth in constant currency for FY17. Show More

Earnings reports: Stockland, CSL, Sonic Healthcare, Primary Health Care & QBE Insurance


Stockland (SGP) posted an 8.5% lift in FY underlying profit to $660m, in-line with consensus. The result was driven by solid performances across all business units – Commercial, Residential and Retirement: Blood products group CSL has reported an 11% decline in FY Net Profit after Tax to US$1,242m. The biotech... Show More


Market Manager | March update – Expect pickup in volatility

Mathan Somasundaram

Large & mid cap talking points: The best 5 multi-factor ideas are QAN, BSL, NCM, LLC and STO while the worst 5 multi-factor ideas are APA, REC, TCL, QUB and ILU. Show More

CSL Half Year Result - CSL beats expectations & assimilates Novartis flu business


CSL, the blood products and vaccine maker, posted a better than expected 3.8% lift in half year profit to US$718.8 million For more Reporting Season coverage, please visit https://www.commsec.com.au/reportingseason Show More

earnings commsec reporting season ASX:CSL csl

Sunset Strip | Aussie Afternoon Institutional Market Wrap

Mathan Somasundaram

Aussie market was directionless with US being closed and gave up the early slight optimism to finish slightly in the red. The market today is best explained through two stocks on either end of sentiment spectrum. SGH has had its life beaten out of it for what market sees as... Show More